In vivo imaging using fluorescent antibodies to tumor necrosis factor predicts therapeutic response in Crohn's disease

被引：0

作者：

Raja Atreya

Helmut Neumann

Clemens Neufert

Maximilian J Waldner

Ulrike Billmeier

Yurdagül Zopf

Marcus Willma

Christine App

Tino Münster

Hermann Kessler

Stefanie Maas

Bernd Gebhardt

Ralph Heimke-Brinck

Eva Reuter

Frank Dörje

Tilman T Rau

Wolfgang Uter

Thomas D Wang

Ralf Kiesslich

Michael Vieth

Ewald Hannappel

Markus F Neurath

机构：

[1] Medical Clinic 1,Department of Biochemistry

[2] Friedrich-Alexander University Erlangen-Nuremberg,Department of Anesthesiology

[3] Friedrich-Alexander University Erlangen-Nuremberg,Department of Surgery

[4] Friedrich-Alexander University Erlangen-Nuremberg,Department of Pharmacy

[5] Friedrich-Alexander University Erlangen-Nuremberg,Department of Pathology

[6] Center for Clinical Studies,Department of Medical Informatics

[7] Friedrich-Alexander University Erlangen-Nuremberg,Division of Gastroenterology

[8] Erlangen University Hospital,undefined

[9] Friedrich-Alexander University Erlangen-Nuremberg,undefined

[10] Friedrich-Alexander University Erlangen-Nuremberg,undefined

[11] Biometry and Epidemiology,undefined

[12] Friedrich-Alexander University Erlangen-Nuremberg,undefined

[13] University of Michigan,undefined

[14] Medical Clinic,undefined

[15] St. Mary's Hospital,undefined

[16] Institute of Pathology,undefined

[17] Klinikum Bayreuth,undefined

来源：

Nature Medicine | 2014年 / 20卷

关键词：

D O I：

暂无

中图分类号：

学科分类号：

摘要：

The use of antibodies against tumour necrosis factor (TNF) has markedly improved the treatment of Crohn's disease, but only certain patients respond to therapy. Here, Raja Atreya and colleagues have developed an approach using topical fluorescent antibodies to TNF and confocal laser endomicroscopy to evaluate the expression of transmembrane TNF (mTNF) in the intestinal mucosa of patients with active Crohn's disease in order to identify patients likely to respond to subsequent treatment with the anti-TNF therapy, adalimumab.

引用

页码：313 / 318

页数：5

共 50 条

[1] In vivo imaging using fluorescent antibodies to tumor necrosis factor predicts therapeutic response in Crohn's disease
Atreya, Raja
Neumann, Helmut
Neufert, Clemens
Waldner, Maximilian J.
Billmeier, Ulrike
Zopf, Yurdaguel
Willma, Marcus
App, Christine
Muenster, Tino
Kessler, Hermann
Maas, Stefanie
Gebhardt, Bernd
Heimke-Brinck, Ralph
Reuter, Eva
Doerje, Frank
Rau, Tilman T.
Uter, Wolfgang
Wang, Thomas D.
Kiesslich, Ralf
Vieth, Michael
Hannappel, Ewald
Neurath, Markus F.
NATURE MEDICINE, 2014, 20 (03) : 313 - 318
[2] ULTRASOUND ELASTICITY IMAGING PREDICTS THERAPEUTIC OUTCOME IN PATIENTS WITH CROHN'S DISEASE TREATED WITH ANTI-TUMOR NECROSIS FACTOR ANTIBODIES
Orlando, S.
Coletta, M.
Fraquelli, M.
Branchi, F.
Magarotto, A.
Conti, B.
Mazza, S.
Conte, D.
Basilisco, G.
Caprioli, F.
DIGESTIVE AND LIVER DISEASE, 2017, 49 : E98 - E98
[3] ULTRASOUND ELASTICITY IMAGING PREDICTS THERAPEUTIC OUTCOME IN PATIENTS WITH CROHN'S DISEASE TREATED WITH ANTITUMOR NECROSIS FACTOR ANTIBODIES
Orlando, Stefania
Fraquelli, Mirella
Coletta, Marina
Branchi, Federica
Magarotto, Andrea
Conti, Clara Benedetta
Mazza, Stefano
Conte, Dario
Basilisco, Guido
Caprioli, Flavio
GASTROENTEROLOGY, 2017, 152 (05) : S606 - S606
[4] Ultrasound Elasticity Imaging Predicts Therapeutic Outcomes of Patients With Crohn's Disease Treated With Anti-Tumour Necrosis Factor Antibodies
Orlando, Stefania
Fraquelli, Mirella
Coletta, Marina
Branchi, Federica
Magarotto, Andrea
Conti, Clara Benedetta
Mazza, Stefano
Conte, Dario
Basilisco, Guido
Caprioli, Flavio
JOURNAL OF CROHNS & COLITIS, 2018, 12 (01): : 63 - 70
[5] Antibodies to tumor necrosis factor-α in the treatment of Crohn's disease
Brown, SJ
Abreu, MT
CURRENT OPINION IN DRUG DISCOVERY & DEVELOPMENT, 2005, 8 (02) : 160 - 168
[6] Endoscopic response to tumor necrosis factor inhibitors predicts long term benefits in Crohn's disease
Ignacio Alfaro
Maria Carme Masamunt
Nuria Planell
Alicia López-García
Jesús Castro
Marta Gallego
Rebeca Barastegui
Angel Giner
Alejandro Vara
Azucena Salas
Elena Ricart
Julián Panés
Ingrid Ordás
World Journal of Gastroenterology, 2019, 25 (14) : 1764 - 1774
[7] Endoscopic response to tumor necrosis factor inhibitors predicts long term benefits in Crohn's disease
Alfaro, Ignacio
Carme Masamunt, Maria
Planell, Nuria
Lopez-Garcia, Alicia
Castro, Jesus
Gallego, Marta
Barastegui, Rebeca
Giner, Angel
Vara, Alejandro
Salas, Azucena
Ricart, Elena
Panes, Julian
Ordas, Ingrid
WORLD JOURNAL OF GASTROENTEROLOGY, 2019, 25 (14) : 1764 - 1774
[8] In Vivo Molecular Imaging Using Fluorescent Anti-TNF Antibodies and Confocal Laser Endomicroscopy Predicts Response to Anti-TNF Therapy in Crohn's Disease
Atreya, Raja
Neumann, Helmut
Neufert, Clemens
Waldner, Maximilian J.
Zopf, Yurdaguel
Willma, Marcus
App, Christine
Muenster, Tino
Kessler, Hermann
Maas, Stefanie
Gebhardt, Bernd
Heimke-Brinck, Ralph
Reuter, Eva
Doerje, Frank
Rau, Tilman T.
Wang, Thomas D.
Kiesslich, Ralf
Vieth, Michael
Hannappel, Ewald
Neurath, Markus F.
GASTROENTEROLOGY, 2013, 144 (05) : S85 - S86
[9] Serum Infliximab, Antidrug Antibodies, and Tumor Necrosis Factor Predict Sustained Response in Pediatric Crohn's Disease
Stein, Ronen
Lee, Dale
Leonard, Mary B.
Thayu, Meena
Denson, Lee A.
Chuang, Emil
Herskovitz, Rita
Kerbowski, Theresa
Baldassano, Robert N.
INFLAMMATORY BOWEL DISEASES, 2016, 22 (06) : 1370 - 1377
[10] Anti-Tumor Necrosis Factor Nonresponders in Crohn's Disease: Therapeutic Strategies
Louis, E.
Belaiche, J.
Reenaers, C.
DIGESTIVE DISEASES, 2009, 27 (03) : 351 - 357

← 1 2 3 4 5 →